| WB | 1/500-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | FIX; P19; PTC; HEMB; THPH8 |
| WB Predicted band size | 52 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human F9 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与F9抗体相关的文献示例(内容基于公开研究整理，非真实文献引用)：
---
1. **文献名称**: *Mechanism of Neutralizing Anti-Factor IX Antibodies in Hemophilia B Patients*
**作者**: Smith, J.R. et al.
**摘要**: 研究分析了血友病B患者中针对凝血因子IX(F9)的中和抗体的产生机制，揭示了抗体通过阻断F9与磷脂膜结合抑制凝血活性的分子路径，为抑制物管理提供新靶点。
2. **文献名称**: *Engineering a Bispecific Antibody Targeting Factor IXa and X for Hemophilia Therapy*
**作者**: Lee, H. & Patel, S.
**摘要**: 报道了一种双特异性抗体设计，可同时结合F9活化形式(FIXa)和FX，模拟天然凝血级联的“tenase复合物”功能，在动物模型中显著改善凝血缺陷。
3. **文献名称**: *Immune Tolerance Induction in Anti-F9 Antibody-Positive Hemophilia B Mice Using Gene Therapy*
**作者**: Zhang, Y. et al.
**摘要**: 通过AAV载体递送F9基因联合免疫调节剂，在小鼠模型中成功诱导免疫耐受，显著降低抗F9抗体滴度，为基因治疗中抑制物问题的解决提供实验依据。
---
注：以上为模拟摘要，实际文献需通过PubMed/Google Scholar等平台检索关键词(如 "Factor IX antibody"、"anti-F9 inhibitors")。
**Background of F9 Antibody**
The F9 antibody is closely associated with coagulation Factor IX, a vitamin K-dependent serine protease critical for blood clotting. Factor IX, encoded by the *F9* gene on the X chromosome, plays a pivotal role in the intrinsic coagulation pathway, where it is activated to Factor IXa and interacts with Factor VIIIa to activate Factor X. Mutations in *F9* lead to Hemophilia B, an X-linked recessive bleeding disorder.
Antibodies targeting Factor IX (commonly called "F9 antibodies") are primarily studied in two contexts: **inhibitors** and **therapeutic/diagnostic tools**. In Hemophilia B patients receiving Factor IX replacement therapy, inhibitory antibodies (neutralizing immunoglobulins) may develop, complicating treatment by accelerating Factor IX clearance or blocking its activity. These inhibitors arise in ~1-5% of severe Hemophilia B cases, posing significant clinical challenges.
Conversely, non-neutralizing F9 antibodies are utilized in diagnostic assays to quantify Factor IX levels or in research to study its structure-function relationships. Recombinant or monoclonal F9 antibodies also hold therapeutic potential, such as in bispecific antibodies mimicking Factor VIII activity (e.g., emicizumab), though this application primarily targets Hemophilia A.
Research on F9 antibodies has advanced understanding of immune responses to clotting factors, guided inhibitor management strategies (e.g., immune tolerance induction), and supported innovations in gene therapy for Hemophilia B. Animal models, like *F9*-knockout mice, remain vital for evaluating antibody-related therapies and coagulation mechanisms.
×
